Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions

The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of—among others—CYP2C19 and CYP3A4. This work presents the development of a whole-body physiologically...

Descripción completa

Detalles Bibliográficos
Autores principales: Loer, Helena Leonie Hanae, Türk, Denise, Gómez-Mantilla, José David, Selzer, Dominik, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145019/
https://www.ncbi.nlm.nih.gov/pubmed/35631502
http://dx.doi.org/10.3390/pharmaceutics14050915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145019/
https://www.ncbi.nlm.nih.gov/pubmed/35631502
http://dx.doi.org/10.3390/pharmaceutics14050915

Ejemplares similares